QQ客服 官方微博 反馈留言

浏览/检索结果: 共5条，第1-5条 帮助 限定条件 发表日期：2019     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 VTE Risk Profiles and Prophylaxis in Medical and Surgical Inpatients The Identification of Chinese Hospitalized Patients' Risk Profile for Venous Thromboembolism (DissolVE-2)-A Cross-sectional Study 期刊论文 CHEST, 2019, 卷号: 155, 期号: 1 作者:  Zhai, Zhenguo;  Kan, Quancheng;  Li, Weimin;  Qin, Xinyu;  Qu, Jieming 收藏  |  浏览/下载：61/0  |  提交时间：2019/12/05 China  prophylaxis  risk profile  VTE   VTE Risk Profiles and Prophylaxis in Medical and Surgical Inpatients The Identification of Chinese Hospitalized Patients' Risk Profile for Venous Thromboembolism (DissolVE-2)-A Cross-sectional Study 期刊论文 CHEST, 2019, 卷号: 155, 页码: 114-122 作者:  Zhai, Zhenguo;  Kan, Quancheng 收藏  |  浏览/下载：61/0  |  提交时间：2019/11/19 VTE  prophylaxis  China  risk profile   VTE Risk Profiles and Prophylaxis in Medical and Surgical Inpatients The Identification of Chinese Hospitalized Patients' Risk Profile for Venous Thromboembolism -A Cross-sectional Study 期刊论文 CHEST, 2019, 卷号: Vol.155 No.1, 页码: 114-122 作者:  Zhai, Zhenguo;  Kan, Quancheng;  Li, Weimin;  Qin, Xinyu;  Qu, Jieming 收藏  |  浏览/下载：54/0  |  提交时间：2019/12/13 VTE  prophylaxis  China  risk profile   VTE Risk Profiles and Prophylaxis in Medical and Surgical Inpatients The Identification of Chinese Hospitalized Patients' Risk Profile for Venous Thromboembolism (DissolVE-2)-A Cross-sectional Study 期刊论文 2019, 卷号: 155, 期号: 1, 页码: 114-122 作者:  Zhai, Zhenguo;  Kan, Quancheng;  Li, Weimin;  Qin, Xinyu;  Qu, Jieming 收藏  |  浏览/下载：39/0  |  提交时间：2020/01/03 China  prophylaxis  risk profile  VTE   Efficacy and safety of ranibizumab 0.5 mg in Chinese patients with visual impairment due to diabetic macular edema: results from the 12-month REFINE study 期刊论文 2019, 卷号: 257, 期号: 3, 页码: 529-541 作者:  Li, Xiaoxin;  Dai, Hong;  Li, Xiaorong;  Han, Mei;  Li, Jun 收藏  |  浏览/下载：172/0  |  提交时间：2020/01/03 Anti-vascular endothelial growth factor  Diabetic macular edema  Pro re nata  Ranibizumab